Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 9/20 | 0.46 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29532989 | 1.00 | FDPS (0.46) | FDPSGGPS1LMNATSHRALDH1A1 | |
| SCHEMBL30510647 | 1.00 | FDPS (0.46) | FDPSGGPS1LMNATSHRALDH1A1 | |
| SCHEMBL30532496 | 1.00 | FDPS (0.46) | FDPSGGPS1LMNATSHRALDH1A1 | |
| SCHEMBL4204835 | 1.00 | FDPS (0.46) | FDPSGGPS1LMNATSHRALDH1A1 | |
| SCHEMBL30510634 | 1.00 | FDPS (0.46) | FDPSGGPS1LMNATSHRALDH1A1 | |
| SCHEMBL28668491 | 1.00 | FDPS (0.46) | FDPSGGPS1LMNATSHRALDH1A1 | |
| SCHEMBL28718184 | 1.00 | FDPS (0.46) | FDPSGGPS1LMNATSHRALDH1A1 | |
| SCHEMBL4204709 | 1.00 | FDPS (0.46) | FDPSGGPS1LMNATSHRALDH1A1 | |
| SCHEMBL21990217 | 1.00 | FDPS (0.46) | FDPSGGPS1LMNATSHRALDH1A1 | |
| SCHEMBL303129 | 1.00 | FDPS (0.46) | FDPSGGPS1LMNATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260071218-A1 | Oral Delivery of Antisense Conjugates Targeting PCSK9 | CIVI BIOPHARMA INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4705454-A2 | COMPOUNDS AND METHODS FOR TREATING HUMAN SUBJECTS | Stoke Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4705455-A1 | COMPOUNDS AND METHODS FOR TREATING HUMAN SUBJECTS | Stoke Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260055409-A1 | COMPOUNDS AND METHODS FOR TREATING HUMAN SUBJECTS | STOKE THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12421516-B2 | Antisense oligomers targeting PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2025-09-23 | — | — | US | disclosed |
| US-12291708-B2 | Oral delivery of antisense conjugates targeting PCSK9 | CIVI BIOPHARMA, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| WO-2024229421-A1 | COMPOUNDS AND METHODS FOR TREATING HUMAN SUBJECTS | STOKE THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| WO-2024227085-A2 | COMPOUNDS AND METHODS FOR TREATING HUMAN SUBJECTS | STOKE THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20240084307-A1 | ANTISENSE OLIGOMERS TARGETING PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2024-03-14 | — | — | US | disclosed |
| US-20240067965-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA INC (US) | 2024-02-29 | — | — | US | disclosed |
| US-7608705-B2 | nucleobases are cytosine groups or mimetics; modified with polyethyleneglycol or a tocopheryl group; useful in inhibiting proliferation of pancreatic tumors | UNIVERSITATSKLINIKUM SCHLESWIG-HOLSTEIN (DE) | 2009-10-27 | — | — | US | disclosed |
| US-20090203132-A1 | PYRROLIDINYL GROUPS FOR ATTACHING CONJUGATES TO OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. | 2009-08-13 | — | — | US | disclosed |
| US-20080199960-A1 | Methods for the Delivery of Oligomeric Compounds | K.U. LEUVEN RESEARCH AND DEVELOPMENT (BE) | 2008-08-21 | — | — | US | disclosed |
| WO-2006031461-A2 | PYRROLIDINYL GROUPS FOR ATTACHING CONJUGATES TO OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| US-20050119470-A1 | Conjugated oligomeric compounds and their use in gene modulation | ISIS PHARMACEUTICALS, INC. | 2005-06-02 | — | — | US | disclosed |
| US-20050019761-A1 | Oligonucleotides, agents containing these oligonucleotides, and the use thereof | UNIVERSITATSKLINIKUM SCHLESWIG-HOLSTEIN (DE) | 2005-01-27 | — | — | US | disclosed |
| WO-2004044141-A2 | CONJUGATED OLIGOMERIC COMPOUNDS AND THEIR USE IN GENE MODULATION | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| EP-1326878-A2 | OLIGONUCLEOTIDES, AGENTS CONTAINING THESE OLIGONUCLEOTIDES, AND THE USE THEREOF | Bayer, Ernst, Prof. Dr. (DE) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002026754-A9 | OLIGONUCLEOTIDES, AGENTS CONTAINING THESE OLIGONUCLEOTIDES, AND THE USE THEREOF | BAYER ERNST (DE) | 2003-05-15 | — | — | WO | disclosed |
| WO-2002026754-A2 | OLIGONUCLEOTIDES, AGENTS CONTAINING THESE OLIGONUCLEOTIDES, AND THE USE THEREOF | BAYER ERNST (DE) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421516-B2 | Antisense oligomers targeting PCSK9 | PCSK9, PCSK7, PCSK6 | FDPS 1861/4885GGPS1 1400/4885LMNA 199/4885 |
| US-20090203132-A1 | PYRROLIDINYL GROUPS FOR ATTACHING CONJUGATES TO OLIGOMERIC COMPOUNDS | PHAX, RIOX2, RNMT | FDPS 1846/4885GGPS1 460/4885LMNA 4212/4885 |
| US-20260071218-A1 | Oral Delivery of Antisense Conjugates Targeting PCSK9 | PCSK9, ALPI, SLC10A2 | FDPS 2294/4885GGPS1 2730/4885LMNA 294/4885 |
| US-20240067965-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | PCSK9, SCD5, PCSK7 | FDPS 1105/4885GGPS1 803/4885LMNA 572/4885 |
| US-20260055409-A1 | COMPOUNDS AND METHODS FOR TREATING HUMAN SUBJECTS | CYFIP1, SYNGR2, CYFIP2 | FDPS 3060/4885GGPS1 2653/4885LMNA 2018/4885 |
| US-12291708-B2 | Oral delivery of antisense conjugates targeting PCSK9 | PCSK9, SCD5, PCSK7 | FDPS 1105/4885GGPS1 803/4885LMNA 572/4885 |
| US-20050119470-A1 | Conjugated oligomeric compounds and their use in gene modulation | PHAX, SNRPE, RRP1B | FDPS 2604/4885GGPS1 2045/4885LMNA 2742/4885 |
| US-20240084307-A1 | ANTISENSE OLIGOMERS TARGETING PCSK9 | PCSK9, PCSK7, PCSK6 | FDPS 1861/4885GGPS1 1400/4885LMNA 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.